Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 meta-analysis

Zhao, 2021
 
NCT04310228
RCTtocilizumab favipiravir COVID-19high
5/7 inconclusive

COVID 19 hospitalized meta-analysis

RCT-TCZ-COVID-19, 2021
 
NCT04346355
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
60/66 inconclusive 112%
RECOVERY, 2021
 
NCT04381936
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
2022/2094 conclusif demonstrated-13% -13%
Soin AS, 2021
 
CTRI/2020/05/025369
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
90/90 inconclusive -30%
Wang, 2020
 
ChiCTR2000029765
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
33/32 safety concern 123%
Colaneri, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
21/21 inconclusive -20%
HNF Hospital Tocilizumab multidisciplinary team, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
20/25 suggested -58%
Martinez-Sanz, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
260/969 suggested -59%
Tsai, 2020 OBStocilizumab controlCOVID 19 hospitalizedserious
66/66 inconclusive 0%

COVID-19 mild to moderate meta-analysis

CORIMUNO-19, 2020
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 mild to moderatesome concern
64/67 inconclusive -7% -39%
EMPACTA, 2020
 
NCT04372186
RCTtocilizumab placeboCOVID-19 mild to moderatesome concern
259/129 conclusif 12% 13% demonstrated-40%
Capra, 2020 OBStocilizumab controlCOVID-19 mild to moderatecritical
62/23 suggested -87%

COVID-19 severe or critically meta-analysis

REMAP-CAP tocilizumab, 2021
 
NCT02735707
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif -27% demonstrated58%
Veiga, 2021
 
NCT04403685
RCTtocilizumab controlCOVID-19 severe or criticallysome concern
65/64 safety concern safety concern149% 49%
BACC Bay Tocilizumab Trial, 2020
 
NCT04356937
RCTtocilizumab placeboCOVID-19 severe or criticallylow
161/81 inconclusive 47% 5% -15%
COVACTA (Rosas), 2020
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
294/144 inconclusive 2% 17%
Andrew, 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
198/413 inconclusive -22%
Biran, 2020 OBStocilizumab controlCOVID-19 severe or criticallyserious
210/420 suggested -32%
Mathilde, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
30/29 suggested -68%
Rojas-Marte, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
96/97 inconclusive -34%
Somers, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
78/76 safety concern -40%
TOCI-RAF Study Group (Campochiaro), 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
32/33 inconclusive -57%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).